Background: Preoperative localization of non-palpable breast lesions is critical for accurate resection and margin control in breast-conserving surgery. Traditional methods, such as wire or radioguided localization, have limitations in terms of logistics, patient comfort, and procedural flexibility. SCOUT®is a wireless, radar-based alternative that may improve surgical precision and workflow. This study aimed to evaluate the clinical performance of the SCOUT®in the localization of non-palpable breast and axillary lesions, including detection success, margin status, reoperation rates, and device-related events. Methods: We conducted a retrospective, single-centre observational study including 427 patients who underwent breast-conserving surgery after preoperative localization using the SCOUT®between January 2023 and May 2024 at a tertiary academic hospital. Variables included lesion type, location, neoadjuvant treatment, device detection, seed deactivation, MRI interference, margin status, and reoperation rate. Results: The mean age was 58 ± 12.7 years, with malignant pathology in 88.5% of cases. SCOUT®achieved a 100% detection rate in axillary localizations and 98.1% in breast lesions. Seed deactivation occurred in 1.2% of cases, all successfully managed intraoperatively. MRI artefacts were observed in 1.6% of patients, without diagnostic interference. Positive margins were reported in 8.3% of cases, representing an improvement compared with the institution’s historic 12% rate, with 5.9% requiring reoperation. Carcinoma in situ showed the highest rate of positive margins, at 26%. Conclusions: SCOUT®was associated with high detection rates, a low incidence of device-related events, and favourable margin outcomes, supporting its reliability for the localization of non-palpable breast lesions.
背景：在保乳手术中，术前对不可触及的乳腺病灶进行精准定位对于实现准确切除和切缘控制至关重要。传统的定位方法，如导丝或放射性示踪定位，在操作流程、患者舒适度和手术灵活性方面存在局限。SCOUT®作为一种基于雷达的无导线定位系统，有望提升手术精准度和工作流程。本研究旨在评估SCOUT®在不可触及的乳腺及腋窝病灶定位中的临床应用表现，包括检测成功率、切缘状态、再手术率及设备相关事件。方法：我们开展了一项回顾性单中心观察性研究，纳入2023年1月至2024年5月期间在一家三级学术医院接受SCOUT®术前定位后行保乳手术的427例患者。分析变量包括病灶类型、位置、新辅助治疗情况、设备检测、定位标记失活、MRI干扰、切缘状态及再手术率。结果：患者平均年龄为58±12.7岁，其中88.5%为恶性病理。SCOUT®在腋窝定位中检测成功率达100%，乳腺病灶检测成功率为98.1%。定位标记失活发生率为1.2%，所有情况均在术中成功处理。1.6%的患者出现MRI伪影，但未影响诊断。切缘阳性率为8.3%，较本院既往12%的历史数据有所改善，其中5.9%需再次手术。原位癌的切缘阳性率最高，达26%。结论：SCOUT®具有较高的检测成功率、较低的设备相关事件发生率以及良好的切缘结果，支持其作为不可触及乳腺病灶定位的可靠技术。
肿瘤(癌症)患者之家